Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy

Bruton tyrosine kinase (BTK) inhibitors are the only FDA-approved treatments for Waldenström macroglobulinemia (WM). Factors prognostic of survival and predictive of response to BTK inhibitors remained to be clarified. We evaluated 319 patients with WM to identify predictive and prognostic factors o...

Descripción completa

Detalles Bibliográficos
Autores principales: Castillo, Jorge J., Sarosiek, Shayna R., Gustine, Joshua N., Flynn, Catherine A., Leventoff, Carly R., White, Timothy P., Meid, Kirsten, Guerrera, Maria L., Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Hunter, Zachary R., Patterson, Christopher J., Branagan, Andrew R., Treon, Steven P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945307/
https://www.ncbi.nlm.nih.gov/pubmed/34965304
http://dx.doi.org/10.1182/bloodadvances.2021006106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945307/
https://www.ncbi.nlm.nih.gov/pubmed/34965304
http://dx.doi.org/10.1182/bloodadvances.2021006106

Ejemplares similares